Luminex (LMNX) 10-Q 5 May 20 2020 Q1 Quarterly report Financial data

COVER PAGE Document

COVER PAGE Document - shares	3 Months Ended
	Mar. 31, 2020	May 04, 2020
COVER PAGE [Abstract]
Entity Central Index Key	0001033905
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	LMNX
City Area Code	(512)
Entity Address, Address Line One	12212 Technology Blvd.,
Entity Incorporation, State or Country Code	DE
Entity File Number	000-30109
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Entity Registrant Name	LUMINEX CORPORATION
Entity Tax Identification Number	74-2747608
Entity Address, City or Town	Austin,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78727
Local Phone Number	219-8020
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		45,789,869
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 43,077	$ 59,173
Accounts Receivable, Net, Current	63,889	55,815
Inventory, Net	78,596	77,084
Other	10,944	10,398
Total current assets	196,506	202,470
Property, Plant and Equipment, Net	64,407	65,515
Intangible Assets, Net (Excluding Goodwill)	87,485	90,336
Goodwill	118,145	118,145
Operating Lease, Right-of-Use Asset	20,487	20,439
Deferred Income Tax Assets, Net	26,657	27,702
Other Assets, Noncurrent	18,236	19,122
Total assets	531,923	543,729
Current liabilities:
Accounts payable	13,236	17,983
Accrued Liabilities, Current	26,751	31,872
Short-term unearned revenue	9,084	8,214
Total current liabilities	49,071	58,069
Long-term unearned revenue	1,606	1,633
Operating Lease, Liability, Noncurrent	16,748	17,182
Other long-term liabilities	1,992	1,985
Total liabilities	69,417	78,869
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock, Value, Outstanding	45	44
Preferred Stock, Value, Outstanding	0	0
Additional Paid in Capital	381,501	380,304
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,443)	(1,380)
Retained earnings	82,403	85,892
Stockholders' Equity Attributable to Parent	462,506	464,860
Liabilities and Equity	$ 531,923	$ 543,729

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	44,602,408	44,325,369
Common Stock, Shares, Outstanding	44,602,408	44,325,369
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

INCOME STATEMENTS

INCOME STATEMENTS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues	$ 90,424	$ 82,408
Cost of Goods and Services Sold	40,078	36,601
Gross margin	50,346	45,807
Research and development	11,918	15,048
Selling, General and Administrative Expense	33,935	31,491
Amortization of Intangible Assets	2,852	2,852
Operating Expenses	48,705	49,391
Operating income	1,641	(3,584)
Other income, net	1	60
Income (Loss) Attributable to Parent, before Tax	1,028	(3,524)
Provision for income taxes	(374)	6,484
Net Income (Loss) Attributable to Parent	654	2,960
Net Income (Loss) Available to Common Stockholders, Basic	634	2,904
Net Income (Loss) Available to Common Stockholders, Diluted	$ 633	$ 2,904
Earnings Per Share [Abstract]
Earnings Per Share, Basic	$ 0.01	$ 0.07
Earnings Per Share, Diluted	$ 0.01	$ 0.07
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted Average Number of Shares Outstanding, Basic	44,404	43,949
Weighted Average Number of Shares Outstanding, Diluted	45,038	44,546
Common Stock, Dividends, Per Share, Declared	$ 0.09	$ 0.06
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ (63)	$ (133)
Other Comprehensive Income (Loss), Net of Tax	(63)	(133)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	591	2,827
Income (Loss) from Equity Method Investments	$ (614)	$ 0

INCOME STATEMENTS INCOME STATEM

INCOME STATEMENTS INCOME STATEMENTS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Operating Expenses	$ 48,705	$ 49,391
Operating Income (Loss)	$ 1,641	$ (3,584)

CASH FLOWS STATEMENTS

CASH FLOWS STATEMENTS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net Income (Loss) Attributable to Parent	$ 654	$ 2,960
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation, Depletion and Amortization	7,434	6,889
Stock-based compensation expense	2,683	2,449
Increase (Decrease) in Deferred Income Taxes	1,053	(8,087)
Gain (Loss) on Disposition of Property Plant Equipment	47	94
Income (Loss) from Equity Method Investments	(614)	0
Other Operating Activities, Cash Flow Statement	(138)	(242)
Changes in operating assets and liabilities:
Accounts receivable	(8,075)	(7,342)
Inventories	(1,510)	(486)
Operating Assets	(501)	2,272
Operating Liabilities	(6,134)	(10,400)
Accounts payable	(4,186)	4,117
Unearned revenue	843	680
Net cash from operations	(7,216)	(7,096)
Net Cash Provided by (Used in) Financing Activities [Abstract]
Common stock issued	1,349	802
Payments Related to Tax Withholding for Share-based Compensation	(2,310)	(2,072)
Common stock cash dividends paid	(4,063)	(2,696)
Net cash used in financing	(5,024)	(3,966)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Additions to property and equipment	(3,923)	(3,823)
Payments for (Proceeds from) Businesses and Interest in Affiliates	(22)	0
Net cash used in investing	(3,901)	(3,823)
Effect of foreign exchange rates on cash and cash equivalents	45	133
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total	(16,096)	(14,752)
Cash and cash equivalents, end of period	$ 43,077	$ 61,689

STOCKHOLDERS' EQUITY STATEMENTS

STOCKHOLDERS' EQUITY STATEMENTS - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated other comprehensive Income (loss)	Retained earnings
Stockholders' Equity Attributable to Parent	$ 464,860	$ 44	$ 380,304	$ (1,380)	$ 85,892
Common Stock, Shares, Outstanding	44,325,369
Stock Issued During Period, Value, Stock Options Exercised	$ 782	$ 0	782	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		224,435
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(2,309)	$ 1	(2,310)	0	0
Stock-based compensation expense	2,683	0	2,683	0	0
Net Income (Loss) Attributable to Parent	654	$ 0	0	0	654
Common stock cash dividends	(4,101)		42		(4,143)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		52,604
Stockholders' Equity Attributable to Parent	462,506	$ 45	381,501	(1,443)	82,403
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (63)	$ 0	$ 0	$ (63)	$ 0
Common Stock, Shares, Outstanding	44,602,408

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Comprehensive Income (Loss) Note [Text Block]	NOTE 7 — OTHER COMPREHENSIVE LOSS Other comprehensive loss represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by, and distributions to, shareholders. Other comprehensive loss for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments. The following table presents the changes in each component of accumulated other comprehensive loss, net of tax (in thousands): Accumulated Other Comprehensive Loss Items - Foreign Currency Balance as of December 31, 2019 $ (1,380) Other comprehensive loss (63) Net current-period other comprehensive loss (63) Balance as of March 31, 2020 $ (1,443) There are no material tax benefits or expenses related to the other comprehensive loss for the three months ended March 31, 2020.

Statement of Financial Position

Statement of Financial Position, Classified (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Cost-method Investments, Realized Losses	$ 205,000
Document Period End Date	Mar. 31, 2020
Cost Method Investments, Original Cost	$ 10,887,000	$ 11,501,000
Prepaid Expense and Other Assets, Noncurrent	1,482,000	1,594,000
Other Assets, Noncurrent	18,236,000	19,122,000
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 5,867,000	$ 6,027,000

Statement of Comprehensive Inco

Statement of Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (1,443)		$ (1,380)
Other Comprehensive Income (Loss), Net of Tax	$ (63)	$ (133)

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 3 — INVENTORIES, NET Inventories are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company routinely assesses its on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. Net inventories consisted of the following (in thousands): March 31, 2020 December 31, 2019 Parts and supplies $ 46,125 $ 45,459 Work-in-progress 15,465 15,532 Finished goods 17,006 16,093 $ 78,596 $ 77,084

FAIR VALUE (Notes)

FAIR VALUE (Notes)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 5 — FAIR VALUE MEASUREMENT Accounting Standards Codification (ASC) 820 “Fair Value Measurement” (ASC 820) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2 or Level 3 measurements for the three-month period ended March 31, 2020. The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 (in thousands): Fair Value Measurements as of March 31, 2020 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 707 $ — $ — $ 707 Equity investment $ — $ — $ 10,887 $ 10,887 Fair Value Measurements as of December 31, 2019 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 707 $ — $ — $ 707 Minority interest investments - short-term $ — $ — $ 22 $ 22 Equity investment $ — $ — $ 11,501 $ 11,501

GOODWILL

GOODWILL	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure [Text Block]	NOTE 6 — GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill is reviewed for impairment at least annually at the beginning of the fourth quarter, or more frequently if impairment indicators arise. A portion of the Company’s goodwill is not expected to be deductible for tax purposes. The changes in the carrying amount of goodwill during the period are as follows (in thousands): March 31, 2020 December 31, 2019 Balance at beginning of period $ 118,145 $ 118,127 Flow cytometry acquisition $ — $ 18 Balance at end of period $ 118,145 $ 118,145

INTANGIBLE ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives): Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2019 Balance as of December 31, 2018 $ 98,469 $ 23,819 $ 10,655 $ 24,013 $ 156,956 Flow cytometry acquisition (116) (428) 1,154 (4,016) (3,406) Balance as of December 31, 2019 98,353 23,391 11,809 19,997 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2018 (40,501) (9,036) (2,271) — (51,808) Amortization expense (7,784) (2,428) (1,194) — (11,406) Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Net balance as of December 31, 2019 $ 50,068 $ 11,927 $ 8,344 $ 19,997 $ 90,336 Weighted average life (in years) 11 10 10 2020 Balance as of March 31, 2020 98,353 23,391 11,809 19,997 $ 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Amortization expense (1,946) (606) (299) — (2,851) Accumulated amortization balance as of March 31, 2020 (50,231) (12,070) (3,764) — (66,065) Net balance as of March 31, 2020 $ 48,122 $ 11,321 $ 8,045 $ 19,997 $ 87,485 Weighted average life (in years) 11 10 10 The Company currently has three IP R&D projects. The first relates to the development of the next generation VERIGENE ® System, VERIGENE II, on which the Company began clinical trials in May 2018. The Company believes the VERIGENE II System will launch commercially in 2020. The second is a defensive IP R&D project related to the Company’s next generation xMAP ® System, xMAP INTELLIFLEX, which the Company also believes will launch commercially in 2020. The third relates to the development of the next generation Guava System (Guava Next Gen System), acquired as part of the Company’s acquisition of EMD Millipore Corporation’s flow cytometry portfolio. The fair value of the Guava Next Gen System IP R&D project was determined using the income approach. The discount rate applied to the projected cash flows was 13.0%, which reflects the engineering and technical risks related to the projects. The Company believes the Guava Next Gen System will also launch commercially in 2020. The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands): 2020 (nine months) $ 8,555 2021 11,048 2022 9,801 2023 9,452 2024 9,452 Thereafter 19,179 $ 67,487

ACCRUED LIABILITIES (Notes)

ACCRUED LIABILITIES (Notes)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 10 — ACCRUED LIABILITIES Accrued liabilities consisted of the following (in thousands): March 31, 2020 December 31, 2019 Compensation and employee benefits $ 11,165 $ 17,011 Dividends payable 4,143 4,104 Income and other taxes 1,402 1,538 Warranty costs 1,557 1,641 Royalties payable 1,431 1,335 Current operating lease liabilities 5,468 5,053 Other 1,585 1,190 $ 26,751 $ 31,872 The following table summarizes the changes in the warranty accrual (in thousands): Accrued warranty costs as of December 31, 2019 $ 1,641 Warranty adjustments/settlements (545) Accrual for warranty costs 461 Accrued warranty costs as of March 31, 2020 $ 1,557

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 12 — INCOME TAXES At the end of each interim reporting period, an estimate is made of the effective tax rate expected to be applicable for the full year. The estimated full year’s effective tax rate is used to determine the income tax rate for each applicable interim reporting period. Tax effects of enacted legislation, including changes in the value of deferred tax assets and liabilities, is recognized in the period of the enactment date. The effective tax rate for the three months ended March 31, 2020 was 36.4%, including amounts recorded for discrete events. This differs from the statutory rate of 21% primarily from the effect of foreign operations. The Company’s tax expense reflects the full federal, various state, and foreign blended statutory rates. The Company currently expects a 2020 full-year effective tax rate of 30% to 40%, excluding amounts recorded for discrete events. The Company will be subject to provisions regarding U.S. federal taxation of foreign intangible income and has included in its estimate of income tax the effects of this tax. The Company is utilizing its net operating losses (NOLs) and tax credits in the U.S., Canada and the Netherlands. In the first quarter of 2020, legislation for coronavirus aid and tax relief was enacted in certain of the jurisdictions in which the Company or one of its subsidiaries files income tax returns. The Company has recorded an immaterial income tax benefit for the effect of tax relief legislation for its Hong Kong subsidiary. Tax relief legislation enacted in the first quarter of 2020 did not affect the Company’s income tax provision in its other jurisdictions at this time, and thus no discrete tax items in other jurisdictions have been recorded. The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, Australia, Canada, China, France, Germany, Hong Kong, Japan, the Netherlands, the U.K., and various U.S. states. Due to NOLs, the U.S., Canadian and Netherlands tax returns dating back to 2016, 2007, and 2013, respectively, can still be reviewed by the taxing authorities. The Company does not expect any material changes to the unrecognized tax benefit liability within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes.

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE 8 — EARNINGS PER SHARE A reconciliation of the denominators used in computing per share net income (EPS) is as follows (in thousands, except per share amounts): Three Months Ended March 31, 2020 2019 Basic: Net income $ 654 $ 2,960 Less: allocation to participating securities (20) (56) Net income attributable to common stockholders $ 634 $ 2,904 Weighted average common stock outstanding 44,404 43,949 Net income per share attributable to common stockholders $ 0.01 $ 0.07 Diluted: Net income $ 654 $ 2,960 Less: allocation to participating securities (21) (56) Net income attributable to common stockholders $ 633 $ 2,904 Weighted average common stock outstanding 44,404 43,949 Effect of dilutive securities: stock options and awards 634 597 Weighted-average shares used in computing net income per share 45,038 44,546 Net income per share attributable to common stockholders $ 0.01 $ 0.07 Basic net income per share is computed by dividing the net income for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock awards (RSAs) and stock options to acquire 1,156,913 and 672,007 shares for the three months ended March 31, 2020 and 2019, respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 — STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Dividends On February 18, 2020, the Board of Directors declared a cash dividend on the Company’s common stock of $0.09 per share. The dividend was payable to stockholders of record as of March 19, 2020 and was paid on April 9, 2020. The Company’s current intent is to pay a continuing dividend on a quarterly basis. However, future declarations of dividends are subject to the final determination of the Company’s Board of Directors. Stock-Based Compensation The Company’s stock option activity for the three months ended March 31, 2020 is as follows: Stock Options Shares Weighted Average Exercise Price Outstanding at December 31, 2019 3,793 $ 20.17 Granted 1,507 23.09 Exercised (60) 16.49 Canceled or expired (550) 24.43 Outstanding at March 31, 2020 4,690 $ 20.66 The Company had $14.8 million of total unrecognized compensation costs related to stock options at March 31, 2020 that are expected to be recognized over a weighted-average period of 3.33 years. The Company’s restricted share activity for the three months ended March 31, 2020 is as follows: Restricted Stock Awards (RSAs) Shares Weighted Average Grant Price Non-vested at December 31, 2019 810 $ 22.28 Granted 407 23.10 Vested (277) 21.47 Cancelled or expired (11) 22.35 Non-vested at March 31, 2020 929 $ 22.88 Restricted Stock Units (RSUs) Shares Non-vested at December 31, 2019 522 Granted 64 Vested (45) Cancelled or expired — Non-vested at March 31, 2020 541 As of March 31, 2020, there were $22.1 million and $3.6 million of unrecognized compensation costs related to RSAs and RSUs, respectively. These costs are expected to be recognized over a weighted average-period of 3.03 years for the RSAs and 2.47 years for the RSUs. The Company issues a small number of cash-settled RSUs pursuant to the Company’s equity incentive plan in certain foreign countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company. The following are the stock-based compensation costs recognized in the Company’s Condensed Consolidated Statements of Comprehensive Income (in thousands): Three Months Ended March 31, 2020 2019 Cost of revenue $ 533 $ 460 Research and development 142 (14) Selling, general and administrative 2,042 2,027 Stock-based compensation costs reflected in net income $ 2,717 $ 2,473

CONTINGENCIES

CONTINGENCIES	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 13 — COMMITMENTS AND CONTINGENCIES In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. When it appears probable in management’s judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements. If only a range of estimated losses can be estimated, we record an amount within the range that, in management’s judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided. Leases We have leased all of our research, manufacturing and office space and have entered into various other agreements in conducting our business. Our leases have remaining lease terms of 1 year to 6 years, and some of our leases include options to extend the leases for up to 10 years, tenant improvement allowances, rent holidays and rent escalation clauses. At inception, we determine whether an agreement represents a lease and at commencement we evaluate each lease agreement to determine whether the lease is an operating or financing lease. As described below under “Note 14 - Recent Accounting Pronouncements - Recently adopted accounting guidance,” the Company adopted the new lease guidance as of January 1, 2019. Pursuant to the new lease guidance, all of the Company’s leases outstanding on January 1, 2019 continued to be classified as operating leases. With the adoption of the new lease guidance, the Company recorded an operating lease right-of-use asset and an operating lease liability on its balance sheet. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit rate, we have used an estimated incremental borrowing rate of 5.75%, based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. For all lease agreements we combine lease and non-lease components. Leases with an initial term of twelve months or less are not recorded on the balance sheet. The components of the lease expense were as follows (in thousands): Three Months Ended Three Months Ended March 31, 2020 March 31, 2019 Operating lease cost (a) $ 2,391 $ 2,345 (a) Includes short-term lease expense costs, which were immaterial in the three months ended March 31, 2020 and 2019. Supplemental cash flow information related to leases was as follows (in thousands): Three Months Ended Three Months Ended March 31, 2020 March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 1,854 $ 1,571 Supplemental balance sheet information related to leases was as follows (in thousands): March 31, 2020 December 31, 2019 Operating leases: Operating lease right-of-use assets $ 20,487 $ 20,439 Operating lease liabilities $ 22,216 $ 22,235 Weighted Average Remaining Lease Term 4.08 years 4.36 years Weighted Average Discount Rate 5.75 % 5.75 % Maturities of lease liabilities for the next five fiscal years and thereafter are as follows (in thousands): Operating Leases 2020 (nine months) $ 5,136 2021 6,685 2022 5,149 2023 4,141 2024 2,981 Thereafter 932 Total lease payments 25,024 Less: imputed interest (2,808) Lease liabilities at March 31, 2020 $ 22,216

RECENT ACCOUNTING (Notes)

RECENT ACCOUNTING (Notes)	3 Months Ended
	Mar. 31, 2020
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 14 — RECENT ACCOUNTING PRONOUNCEMENTS Recently adopted accounting guidance In June 2016, the FASB issued guidance on financial instruments and related credit losses. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The statement of comprehensive income reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2020. The Company adopted the new standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company does not have a history of significant credit losses and this guidance did not have a material impact on its consolidated financial statements.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recent accounting guidance not yet adopted In December 2019, the FASB issued final guidance that simplifies the accounting for income taxes by eliminating some exceptions to the general approach in Accounting Standards Codification 740, Income Taxes. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance includes provisions for investment company reporting modernization, amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, and is applicable for the Company in fiscal 2021. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.

REVENUE RECOGNITION (Notes)

REVENUE RECOGNITION (Notes)	3 Months Ended
	Mar. 31, 2020
Revenue Recognition and Deferred Revenue [Abstract]
Revenue Recognition, Deferred Revenue [Policy Text Block]	NOTE 11 — REVENUE RECOGNITION The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606 “Revenue from Contracts with Customers” (the Standard), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of the Standard, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling price of the promised good or service underlying each performance obligation and recognizes this as revenue when such performance obligation is satisfied. US Government Contracts In March 2020, the Biomedical Advanced Research and Development Authority (BARDA) awarded the Company two milestone-based contracts, with a value of $642,450 each, funding approximately 36% of the expected overall cost of development. BARDA is part of the U.S. Department of Health and Human Services and is tasked with protecting the U.S. against emerging infectious diseases and other threats. Through public-private partnerships, BARDA supports the development of vaccines, drugs, and diagnostics. One of BARDA’s current goals is to develop medical countermeasures to enhance health security and protect against 2019 novel coronavirus infections (COVID-19). The Company’s management believes these two contracts help to enable an expansion of the Company’s current portfolio of diagnostics for SARS-COV-2. The Company recorded government contract revenue of $642,450 for the quarter ended March 31, 2020 as all of the milestones were completed for the first BARDA contract. Contract assets are included within accounts receivables, net and contract liabilities are included in deferred revenue on the Company’s Condensed Consolidated Balance Sheets. The following table presents the opening and closing balances of the Company’s contract assets and liabilities as of March 31, 2020 (in thousands): Balance as of March 31, 2020 Balance as of December 31, 2019 Contract assets: Unbilled receivables - Royalties $ 13,655 $ 12,257 Unbilled receivables - Other 642 — Total contract assets $ 14,297 $ 12,257 Contract liabilities - Short-term: Deferred revenue - Service $ 8,761 $ 7,771 Deferred revenue - Licenses 202 207 Deferred revenue - Instruments 5 2 Deferred revenue - Other 115 234 Total contract liabilities - Short-term $ 9,083 $ 8,214 Contract liabilities - Long-term: Deferred revenue - Service $ 990 $ 968 Deferred revenue - Licenses 616 665 Total contract liabilities - Long-term $ 1,606 $ 1,633 During the three months ended March 31, 2020, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the period (in thousands): Three Months Ended March 31, 2020 Revenue recognized in the period: Amounts included as contract liabilities at the beginning of the period $ 2,738 Performance obligations satisfied in previous periods -

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Business Description and Accounting Policies [Text Block]	NOTE 1 — BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the Company or Luminex) in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (the 2019 10-K).

Receivables, Loans, Notes Recei

Receivables, Loans, Notes Receivable, and Others (Policies)	3 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Accounts Receivable	NOTE 4 — ACCOUNTS RECEIVABLE AND RESERVES The Company adopted the new credit loss standard effective January 1, 2020. The primary impact for the Company was the timing of recording expected credit losses on its trade receivables. The Company’s allowance for doubtful accounts is based upon its expected credit losses, based upon its historical loss experience. Management prepared an analysis of partner versus non-partner credit loss experience and noted that its loss experience between partners and non-partners was very comparable. These receivables have been pooled together as similar risk characteristics exist. Accounts receivable consisted of the following (in thousands): March 31, 2020 December 31, 2019 Accounts receivable 65,294 56,956 Less: Allowance for doubtful accounts (1,405) (1,141) 63,889 55,815 Balance as of December 31, 2019 $ 1,141 Net increases charged to costs and expenses 436 Write-offs of uncollectible accounts (172) Balance as of March 31, 2020 $ 1,405

INVESTMENTS (Tables)

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Other Investments Not Readily Marketable [Table Text Block]	March 31, 2020 December 31, 2019 Purchased technology rights (net of accumulated amortization of $8,459 and $8,300 on March 31, 2020 and December 31, 2019, respectively) $ 5,867 $ 6,027 Minority interest investments 10,887 11,501 Other 1,482 1,594 $ 18,236 $ 19,122
Marketable Securities [Table Text Block]	Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707
Cost-method Investments, Description [Text Block]	Non-Marketable Securities and Other-Than-Temporary Impairment During the year ended December 31, 2018, the Company made a $1.8 million investment in Combinati, a private company. On October 1, 2019 the Company made an additional $7.0 million investment in Combinati, bringing the Company's ownership to approximately 28.4% of the voting interest of Combinati. Effective October 1, 2019, the Company accounted for its investment in Combinati under the equity method, given the Company's significant influence over the investee due to its larger ownership percentage and its participation on the Board of Directors. The Company does not have unilateral decision making power, and therefore will not consolidate the investee. In the fourth quarter of 2019, we remeasured the existing, minority interest investment based on the fair value prior to the additional investment and recorded a gain of approximately $3.2 million in Other income, net in the Consolidated Statements of Comprehensive Income. The minority interest investment in Combinati was reclassified to equity method investments to distinguish it from other minority interest investments that take the fair value alternative. As of March 31, 2020, the carrying value of the Company’s total investment in Combinati was $10.9 million, which exceeded the Company’s share of Combinati’s net assets by $7.6 million. For the quarter ended March 31, 2020, the Company recorded $0.6 million for its allocable share of Combinati’s net loss in its Consolidated Statement of Comprehensive Income and as an adjustment to the invested balance. The Company owned a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We were informed that this private company was dissolving and ceasing operations in 2019. We recorded an impairment of $160,000 and $45,000 in Other income, net in the Consolidated Statements of Comprehensive Income during the second quarter and fourth quarter of 2019, respectively. We received the final cash payment for the remainder of our investment in the first quarter of 2020. These investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the $205,000 impairment in 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments. As the inputs utilized for the Company’s periodic impairment assessment are not based on observable market data, the determination of fair value of its investments is classified within Level 3 of the fair value hierarchy. See Note 5 - Fair Value Measurement to our Condensed Consolidated Financial Statements for further information on the fair value hierarchy and the three classification levels. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, an investment’s fair value is not estimated as there are no identified events or changes in the circumstances. There have been no unrealized gains or losses related to these Level 3 minority interest investments.
Investments and Other Noncurrent Assets [Text Block]	NOTE 2 — INVESTMENTS AND OTHER ASSETS Marketable Securities The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. As of March 31, 2020, the Company had no short or long-term investments, since those funds were used to pay for acquisitions. Available-for-sale securities consisted of the following as of March 31, 2020 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707 Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707 There were no proceeds from the sales of available-for-sale securities for the three months ended March 31, 2020 and the year ended December 31, 2019. Realized gains and losses on sales of investments are determined using the specific identification method and are included in Other income, net in the Condensed Consolidated Statements of Comprehensive Income. There were no available-for-sale debt securities as of March 31, 2020 or December 31, 2019. All of the Company’s available-for-sale securities with gross unrealized losses as of March 31, 2020 had been in a loss position for less than 12 months. Non-Marketable Securities and Other-Than-Temporary Impairment During the year ended December 31, 2018, the Company made a $1.8 million investment in Combinati, a private company. On October 1, 2019 the Company made an additional $7.0 million investment in Combinati, bringing the Company's ownership to approximately 28.4% of the voting interest of Combinati. Effective October 1, 2019, the Company accounted for its investment in Combinati under the equity method, given the Company's significant influence over the investee due to its larger ownership percentage and its participation on the Board of Directors. The Company does not have unilateral decision making power, and therefore will not consolidate the investee. In the fourth quarter of 2019, we remeasured the existing, minority interest investment based on the fair value prior to the additional investment and recorded a gain of approximately $3.2 million in Other income, net in the Consolidated Statements of Comprehensive Income. The minority interest investment in Combinati was reclassified to equity method investments to distinguish it from other minority interest investments that take the fair value alternative. As of March 31, 2020, the carrying value of the Company’s total investment in Combinati was $10.9 million, which exceeded the Company’s share of Combinati’s net assets by $7.6 million. For the quarter ended March 31, 2020, the Company recorded $0.6 million for its allocable share of Combinati’s net loss in its Consolidated Statement of Comprehensive Income and as an adjustment to the invested balance. The Company owned a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We were informed that this private company was dissolving and ceasing operations in 2019. We recorded an impairment of $160,000 and $45,000 in Other income, net in the Consolidated Statements of Comprehensive Income during the second quarter and fourth quarter of 2019, respectively. We received the final cash payment for the remainder of our investment in the first quarter of 2020. These investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the $205,000 impairment in 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments. As the inputs utilized for the Company’s periodic impairment assessment are not based on observable market data, the determination of fair value of its investments is classified within Level 3 of the fair value hierarchy. See Note 5 - Fair Value Measurement to our Condensed Consolidated Financial Statements for further information on the fair value hierarchy and the three classification levels. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, an investment’s fair value is not estimated as there are no identified events or changes in the circumstances. There have been no unrealized gains or losses related to these Level 3 minority interest investments. Other long-term assets consisted of the following (in thousands): March 31, 2020 December 31, 2019 Purchased technology rights (net of accumulated amortization of $8,459 and $8,300 on March 31, 2020 and December 31, 2019, respectively) $ 5,867 $ 6,027 Minority interest investments 10,887 11,501 Other 1,482 1,594 $ 18,236 $ 19,122 For the three months ended March 31, 2020 and 2019, the Company recognized amortization expenses related to the amortization of purchased technology rights of approximately $159,000 and $162,000, respectively. Future amortization expenses are estimated to be $413,000 in the remaining nine months of 2020, $540,000 in 2021, $522,000 in 2022, $505,000 in 2023, $500,000 in 2024 and $3,387,000 thereafter.
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Marketable Securities The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. As of March 31, 2020, the Company had no short or long-term investments, since those funds were used to pay for acquisitions. Available-for-sale securities consisted of the following as of March 31, 2020 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707 Available-for-sale securities consisted of the following as of December 31, 2019 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 707 $ — $ — $ 707 Total current securities 707 — — 707 Total available-for-sale securities $ 707 $ — $ — $ 707 There were no proceeds from the sales of available-for-sale securities for the three months ended March 31, 2020 and the year ended December 31, 2019. Realized gains and losses on sales of investments are determined using the specific identification method and are included in Other income, net in the Condensed Consolidated Statements of Comprehensive Income. There were no available-for-sale debt securities as of March 31, 2020 or December 31, 2019. All of the Company’s available-for-sale securities with gross unrealized losses as of March 31, 2020 had been in a loss position for less than 12 months.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2020
Inventory Disclosure [Abstract]
Components of Inventories	March 31, 2020 December 31, 2019 Parts and supplies $ 46,125 $ 45,459 Work-in-progress 15,465 15,532 Finished goods 17,006 16,093 $ 78,596 $ 77,084

FAIR VALUE (Tables)

FAIR VALUE (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]	Fair Value Measurements as of March 31, 2020 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 707 $ — $ — $ 707 Equity investment $ — $ — $ 10,887 $ 10,887

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2019 Balance as of December 31, 2018 $ 98,469 $ 23,819 $ 10,655 $ 24,013 $ 156,956 Flow cytometry acquisition (116) (428) 1,154 (4,016) (3,406) Balance as of December 31, 2019 98,353 23,391 11,809 19,997 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2018 (40,501) (9,036) (2,271) — (51,808) Amortization expense (7,784) (2,428) (1,194) — (11,406) Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Net balance as of December 31, 2019 $ 50,068 $ 11,927 $ 8,344 $ 19,997 $ 90,336 Weighted average life (in years) 11 10 10 2020 Balance as of March 31, 2020 98,353 23,391 11,809 19,997 $ 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2019 (48,285) (11,464) (3,465) — (63,214) Amortization expense (1,946) (606) (299) — (2,851) Accumulated amortization balance as of March 31, 2020 (50,231) (12,070) (3,764) — (66,065) Net balance as of March 31, 2020 $ 48,122 $ 11,321 $ 8,045 $ 19,997 $ 87,485 Weighted average life (in years) 11 10 10
Estimated Future Amortization Expense Related to Intangible Assets	2020 (nine months) $ 8,555 2021 11,048 2022 9,801 2023 9,452 2024 9,452 Thereafter 19,179 $ 67,487

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2020 December 31, 2019 Compensation and employee benefits $ 11,165 $ 17,011 Dividends payable 4,143 4,104 Income and other taxes 1,402 1,538 Warranty costs 1,557 1,641 Royalties payable 1,431 1,335 Current operating lease liabilities 5,468 5,053 Other 1,585 1,190 $ 26,751 $ 31,872
Schedule of Product Warranty Liability [Table Text Block]	Accrued warranty costs as of December 31, 2019 $ 1,641 Warranty adjustments/settlements (545) Accrual for warranty costs 461 Accrued warranty costs as of March 31, 2020 $ 1,557

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Basic and Diluted Earnings Per Share	Three Months Ended March 31, 2020 2019 Basic: Net income $ 654 $ 2,960 Less: allocation to participating securities (20) (56) Net income attributable to common stockholders $ 634 $ 2,904 Weighted average common stock outstanding 44,404 43,949 Net income per share attributable to common stockholders $ 0.01 $ 0.07 Diluted: Net income $ 654 $ 2,960 Less: allocation to participating securities (21) (56) Net income attributable to common stockholders $ 633 $ 2,904 Weighted average common stock outstanding 44,404 43,949 Effect of dilutive securities: stock options and awards 634 597 Weighted-average shares used in computing net income per share 45,038 44,546 Net income per share attributable to common stockholders $ 0.01 $ 0.07

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory, Raw Materials and Purchased Parts, Net of Reserves	$ 46,125	$ 45,459
Inventory, Work in Process, Net of Reserves	15,465	15,532
Inventory, Finished Goods, Net of Reserves	17,006	16,093
Inventory, Net	$ 78,596	$ 77,084

Receivables, Loans, Notes Rec_2

Receivables, Loans, Notes Receivable, and Others (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Receivables [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 1,405	$ 1,141
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)	436
Accounts Receivable, Allowance for Credit Loss, Writeoff	$ 172

FAIR VALUE (Details)

FAIR VALUE (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 707	$ 707
Cost Method Investments, Fair Value Disclosure	10,887	11,501
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	707	707
Cost Method Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Cost Method Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Cost Method Investments, Fair Value Disclosure	$ 10,887	$ 11,501

GOODWILL (Details)

GOODWILL (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 118,145		$ 118,145	$ 118,127
Goodwill, Acquired During Period	$ 0	$ 18

INTANGIBLE ASSETS (Detail)

INTANGIBLE ASSETS (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	$ 8,555
Finite-Lived Intangible Assets, Accumulated Amortization	(66,065)		$ (63,214)	$ (51,808)
Indefinite-lived Intangible Assets (Excluding Goodwill)	19,997		19,997	24,013
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	19,179
Finite-Lived Intangible Assets, Amortization Expense, Year Three	9,801
Finite-Lived Intangible Assets, Amortization Expense, Year Two	11,048
Finite-Lived Intangible Assets, Amortization Expense, Year Four	9,452
Finite-Lived Intangible Assets, Amortization Expense, Year Five	9,452
Intangible Assets, Net (Excluding Goodwill)	87,485		90,336
Intangible Assets, Gross (Excluding Goodwill)	153,550		153,550	156,956
Amortization of Intangible Assets, IA	(2,852)	$ (2,852)	(11,406)
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments			(4,016)
Employee Benefits and Share-based Compensation	2,717	$ 2,473
Contract with Customer, Liability, Revenue Recognized	2,738
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(50,231)		(48,285)	(40,501)
Finite-Lived Intangible Assets, Gross	98,353		98,353	98,469
Finite-Lived Intangible Assets, Net	$ 48,122		$ 50,068
Finite-Lived Intangible Asset, Useful Life	11 years		11 years
Amortization of Intangible Assets, IA	$ (1,946)		$ (7,784)
Finite-Lived Intangible Assets, Purchase Accounting Adjustments			(116)
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(12,070)		(11,464)	(9,036)
Finite-Lived Intangible Assets, Gross	23,391		23,391	23,819
Finite-Lived Intangible Assets, Net	$ 11,321		$ 11,927
Finite-Lived Intangible Asset, Useful Life	10 years		10 years
Amortization of Intangible Assets, IA	$ (606)		$ (2,428)
Finite-Lived Intangible Assets, Purchase Accounting Adjustments			(428)
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(3,764)		(3,465)	(2,271)
Finite-Lived Intangible Assets, Gross	11,809		11,809	$ 10,655
Finite-Lived Intangible Assets, Net	$ 8,045		$ 8,344
Finite-Lived Intangible Asset, Useful Life	10 years		10 years
Amortization of Intangible Assets, IA	$ (299)		$ (1,194)
Finite-Lived Intangible Assets, Purchase Accounting Adjustments			$ 1,154

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Employee-related Liabilities, Current	$ 11,165	$ 17,011
Taxes Payable, Current	1,402	1,538
Product Warranty Accrual, Current	1,557	1,641
Accrued Royalties, Current	1,431	1,335
Operating Lease, Liability, Current	5,468	5,053
Standard and Extended Product Warranty Accrual, Decrease for Payments	(461)
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued	545
Dividends Payable, Current	4,143	4,104
Other Accrued Liabilities, Current	1,585	1,190
Accrued Liabilities, Current	$ 26,751	$ 31,872

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	36.40%
U.S. federal statutory tax rate	21.00%
Provision for income taxes	$ 374	$ (6,484)
Income (Loss) Attributable to Parent, before Tax	$ 1,028	$ (3,524)

EARNINGS PER SHARE Details (Det

EARNINGS PER SHARE Details (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic	$ (20)	$ (56)
Net Income (Loss) Available to Common Stockholders, Basic	$ 634	$ 2,904
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,156,913	672,007
Net Income (Loss) Available to Common Stockholders, Diluted	$ 633	$ 2,904
Weighted Average Number of Shares Outstanding, Basic	44,404,000	43,949,000
Earnings Per Share, Basic	$ 0.01	$ 0.07
Net Income (Loss) Attributable to Parent	$ 654	$ 2,960
Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted	$ (21)	$ (56)
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	634,000	597,000
Weighted Average Number of Shares Outstanding, Diluted	45,038,000	44,546,000
Earnings Per Share, Diluted	$ 0.01	$ 0.07

STOCKHOLDERS' EQUITY Details (D

STOCKHOLDERS' EQUITY Details (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends Payable, Date Declared	Feb. 18, 2020
Dividends Payable, Date of Record	Mar. 19, 2020
Dividends Payable, Date to be Paid	Apr. 9, 2020
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 14.8
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	541	522
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	64
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(45)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 5 months 19 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 3.6
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	929	810
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 22.88	$ 22.28
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	407
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 23.10
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(277)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 21.47
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(11)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$ 22.35
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 10 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 22.1
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 3 months 29 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,690	3,793
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 20.66	$ 20.17
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,507
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 23.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(60)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 16.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	(550)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price	$ 24.43

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	4 years 29 days		4 years 4 months 9 days
Lease, Cost	$ 2,391	$ 2,345
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	5,136
Operating Leases, Future Minimum Payments, Due in Two Years	6,685
Operating Leases, Future Minimum Payments, Due in Three Years	5,149
Operating Leases, Future Minimum Payments, Due in Four Years	4,141
Operating Leases, Future Minimum Payments, Due in Five Years	2,981
Operating Leases, Future Minimum Payments, Due Thereafter	932
Operating Leases, Future Minimum Payments Due	$ 25,024
Operating Lease, Weighted Average Discount Rate, Percent	5.75%		5.75%
Operating Lease, Payments	$ 1,854	$ 1,571

REVENUE RECOGNITION (Details)

REVENUE RECOGNITION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue Recognition and Deferred Revenue [Abstract]
Lease, Cost	$ 2,391	$ 2,345